Cite
HARVARD Citation
Yan, X. et al. (2019). Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation. Lung cancer. pp. 6-12. [Online].